Highbridge Capital Management LLC Increases Stake in OnKure Therapeutics, Inc. $OKUR

Highbridge Capital Management LLC boosted its stake in OnKure Therapeutics, Inc. (NASDAQ:OKUR) by 51.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 663,607 shares of the company’s stock after purchasing an additional 224,810 shares during the quarter. Highbridge Capital Management LLC owned about 4.91% of OnKure Therapeutics worth $1,586,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Affinity Asset Advisors LLC raised its stake in OnKure Therapeutics by 173.4% during the first quarter. Affinity Asset Advisors LLC now owns 394,159 shares of the company’s stock worth $1,695,000 after purchasing an additional 250,000 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of OnKure Therapeutics during the 1st quarter worth $43,000. Finally, Bailard Inc. purchased a new position in shares of OnKure Therapeutics in the 2nd quarter worth $34,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wall Street Zen raised OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Zacks Research lowered OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OnKure Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of OnKure Therapeutics in a report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, OnKure Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.33.

OnKure Therapeutics Price Performance

Shares of OKUR opened at $2.62 on Friday. The stock’s 50-day moving average is $2.90 and its two-hundred day moving average is $2.60. The stock has a market cap of $35.50 million, a PE ratio of -0.55 and a beta of 0.46. OnKure Therapeutics, Inc. has a 12 month low of $1.70 and a 12 month high of $16.15.

OnKure Therapeutics (NASDAQ:OKUR) last posted its earnings results on Thursday, November 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.11. On average, research analysts anticipate that OnKure Therapeutics, Inc. will post -4.05 earnings per share for the current year.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.